Find another Doctor or Researcher

A photo of Russell Ware.
High Res

Russell E. Ware, MD, PhD

Director, Division of Hematology

Institute Co-Director, Cancer and Blood Diseases Institute

Associate Director, Global Health Center                                     

Marjory J. Johnson Chair of Hematology Translational Research

Academic Affiliations

Professor, UC Department of Pediatrics

Phone 513-803-4597

Fax 513-803-8941

Email russell.ware@cchmc.org

Specialties
Hide
Sickle cell disease; hemolytic anemia; immune-mediated cytopenia; PNH
Visit the Ware Lab.
Biography
Hide
Russell Ware, MD, PhD, has been involved with a wide variety of clinical and translational hematology research projects for over 25 years, but his primary interests have focused on sickle cell disease. Dr. Ware has substantial personal experience with directing patient-oriented research, and he currently runs an NIH-funded laboratory effort that investigates genetic modifiers of sickle cell disease. The main focus of his lab research is to understand the phenotypic variability that occurs with hydroxyurea treatment, through the study of hydroxyurea pharmacokinetics, pharmacodynamics, pharmacogenetics, and pharmacogenomics. Dr. Ware is also the national principal investigator for several NIH-funded multicenter sickle cell clinical trials, including the recently completed Stroke With Transfusions Changing to Hydroxyurea (SWiTCH), and the current TCD With Transfusions Changing to Hydroxyurea (TWiTCH) and Sparing Conversion to Abnormal TCD Elevations (SCATE) studies that include non-US clinical sites. Most recently, Dr. Ware has moved his research efforts into the international arena, starting SCD pilot screening programs in Angola, and now conducting clinical trials to determine the safety and efficacy of hydroxyurea in developing countries.
Education and Training
Hide

MD: Duke University School of Medicine, Durham, NC, 1979-83.

Residency: Baylor College of Medicine, Houston, TX, 1983-86.

Fellowship: Duke Medical Center, Durham, NC, 1986-89.

PhD: Duke University School of Medicine, Durham, NC, 1987-91.

Certification: Pediatric Hematology/Oncology.

Publications
Hide

Ndeezi G, Kiyaga C, Hernandez AG, Munube D, Howard TA, Ssewanyana I, Nsungwa J, Kiguli S, Ndugwa CM, Ware RE, Aceng JR. Burden of sickle cell trait and disease in the Uganda Sickle Surveillance Study (US3): a cross-sectional study. Lancet Glob Health. 2016 Mar;4(3):e195-e200.

Aygun B, Mortier NA, Kesler K, Schultz WH, Alvarez O, Rogers Z, Kwiatkowski J, Miller S, Sylvestre P, Cohen A, Ware RE. Therapeutic phlebotomy is safe in children with sickle cell anemia and can be effective treatment for transfusional iron overload. Br J Haematol. 2015;169(2):262-266.

Ware RE, Davis BR, Schultz WH, Brown, Aygun B, Sarnaik S, Odame I, Fuh B, George A, Owen W, Luchtman-Jones L, Rogers ZR, Hilliard L, Gauger C, Piccone C, Lee MT, Kwiatkowski JL, Jackson S, Miller ST, Roberts C, Heeney MM, Kalfa TA, Nelson S, Imran H, Nottage K, Alvarez O, Rhodes M, Thompson AA, Rothman JA, Helton KJ, Roberts D, Coleman J, Bonner MJ, Kutlar A, Patel N, Wood J, Piller L, Wei P, Luden J, Mortier NA, Stuber SE, Luban NL, Cohen AR, Pressel, Adams RJ. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet. 2015 Feb;387(10019):661-670.

Yawn BP, Buchanan GR, Afenyi-Annan AN, Ballas SK, Hassell KL, James AH, Jordan L, Lanzkron SM, Lottenberg R, Savage WJ, Tanabe PJ, Ware RE, Murad MH, Goldsmith JC, Ortiz E, Fulwood R, Horton A, John-Sowah J. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014 Sep 10;312(10):1033-48.

Ware RE. Is sickle cell anemia a neglected tropical disease? PLoS Negl Trop Dis. 2013 May 30;7(5):e2120.

Ware RE and Helms RW for the SWiTCH Investigators. Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood. 2012;119(17):3925-3932.

Ware RE, Despotovic JM, Mortier NA, Flanagan JM, He J, Smeltzer M, Kimble AC, Aygun B, Wu S, Howard T, Sparreboom A. Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia. Blood. 2011;118(18):4985-4991.

Wang WC, Ware RE, Miller ST, Iyer RV, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicenter, randomized, controlled trial (BABY HUG). Lancet. 2011;377(9778):1663-1672.

Ware RE, Zimmerman SA, Sylvestre PB, Mortier NA, Davis JS, Treem WR, Schultz WH. Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy. J Pediatr. 2004;145:346-352.

Zimmerman SA, Schultz WH, Davis JS, Pickens CV, Mortier NA, Howard TA, Ware RE. Sustained long-term hematological efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood. 2004;103:2039-2045.

Related Professionals

Donate Now

3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462

New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479

© 1999-2017 Cincinnati Children's Hospital Medical Center. All rights reserved.

Visit U.S. News site. Best Places to Work Logo